Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794015 | 0.81 | BTK (0.60) | BTKEPHX2P2RX7 | |
| SCHEMBL16794372 | 0.80 | PRMT5 (0.56) | EPHX2ROCK1PRMT5WDR77 | |
| SCHEMBL22659448 | 0.78 | EPHX2 (0.42) | EPHX2P2RX7ROCK1PRMT5WDR77 | |
| SCHEMBL16793852 | 0.75 | BTK (0.47) | BTKEPHX2ROCK1PRMT5WDR77 | |
| SCHEMBL28125942 | 0.75 | BTK (0.54) | BTKEPHX2P2RX7 | |
| SCHEMBL17645747 | 0.74 | EPHX2 (0.51) | BTKEPHX2 | |
| SCHEMBL20027005 | 0.73 | BTK (0.41) | BTKEPHX2ROCK1PRMT5WDR77 | |
| SCHEMBL29925576 | 0.72 | EPHX2 (0.40) | EPHX2ROCK1PRMT5WDR77 | |
| SCHEMBL16793886 | 0.72 | BTK (0.66) | BTKEPHX2P2RX7 | |
| SCHEMBL15897796 | 0.72 | ROCK1 (0.43) | EPHX2ROCK1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | BIOGEN MA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2019-07-18 | — | — | US | disclosed |
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-04-05 | — | — | US | disclosed |
| US-9809577-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885P2RX7 4019/4885 |
| US-10759783-B2 | Biaryl inhibitors of Bruton'S tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885P2RX7 4019/4885 |
| US-20180093973-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885P2RX7 4019/4885 |
| US-20190218204-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885P2RX7 4019/4885 |
| US-20160311802-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885EPHX2 1900/4885P2RX7 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.